




Colin MD  Broom - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Colin MD  Broom
Check out list of companies and businesses related to Colin MD  Broom. Find out Colin MD  Broom address and contact details. View other people related to Colin MD  Broom - coworkers, colleagues, companions, etc.
Address:   

405 EAGLEVIEW BOULEVARD  EXTON 19341 PA




Companies related to Colin MD  Broom
CIKCompany NamePositionCompany Address0000890465NPS PHARMACEUTICALS INCDirector 550 HILLS DRIVE  BEDMINSTER 079210000946840VIROPHARMA INCVP & Chief Scientific Officer 730 STOCKTON DRIVE  EXTON 193410001641640Nabriva Therapeutics plcChief Executive Officer 56 FITZWILLIAM SQUARE  DUBLIN 20001703287Nabriva Therapeutics Legacy plcChief Executive Officer 56 FITZWILLIAM SQUARE  DUBLIN 2




Colin MD  Broom on the Web
Persons related to Colin MD  Broom - NPS PHARMACEUTICALS INCNamePositionCityVal R  AntczakSenior VP, Legal Affairs SALT LAKE CITYLUKE M  BESHAREVP & CFO EAST RUTHERFORDLUKE M  BESHARBEDMINSTERBIOTECHNOLOGY VALUE FUND II LPCHICAGOBIOTECHNOLOGY VALUE FUND L PCHICAGOMICHAEL W  BONNEYDirector LEXINGTONMICHAEL W  BONNEYDirector SALT LAKE CITYMICHAEL W  BONNEYDirector BEDMINSTERColin MD  BroomDirector EXTONColin MD  BroomDirector BEDMINSTERMORGAN R  BROWNVice President, Finance SALT LAKE CITYMORGAN R  BROWNVice President, Finance SALT LAKE CITYNANCY  BRYANSVP, Commercial Operations BEDMINSTERBVF INC/ILCHICAGOBVF INVESTMENTS LLCCHICAGOBVF PARTNERS L P/ILCHICAGODAVID L  CLARKVP, Corporate Affairs SALT LAKE CITYDAVID L  CLARKVP, Corporate Affairs SALT LAKE CITYN ANTHONY  COLESCEO, President and Director SALT LAKE CITYN ANTHONY  COLESPresident, COO & Director BEDMINSTERSANTO J  COSTADirector SALT LAKE CITYSANTO J  COSTADirector SALT LAKE CITYSANDRA  COTTRELLVP, Regulatory Affairs & Drug BEDMINSTERChristine Mikail  CvijicSVP, Legal Affairs & GC SEATTLEChristine Mikail  CvijicSVP, Legal Affairs & GC BEDMINSTERDOUGLAS N  DOBAKBEDMINSTERDOUGLAS N  DOBAKVP, Regulatory Affairs BEDMINSTERJOHN ROBERT  EVANSDirector SALT LAKE CITYJOHN ROBERT  EVANSDirector SALT LAKE CITYPaul E  FirutaPresident, US Comm Operations BEDMINSTERPaul E  FirutaPresident, US Comm Operations BEDMINSTERRobin D  FriedmanSVP of Human Resources BEDMINSTERROGER  GARCEAUSVP & CMO BEDMINSTERROGER  GARCEAUSVP & CMO BEDMINSTERGEORGES  GEMAYELDirector CAMBRIDGEGEORGES  GEMAYELDirector BEDMINSTERSusan E  GrafVP,Corp Development & Strategy BEDMINSTERPEDRO P  GRANADILLODirector PEDRO P  GRANADILLODirector BEDMINSTERJAMES G  GRONINGERDirector SALT LAKE CITYJAMES G  GRONINGERDirector SALT LAKE CITYJAMES G  GRONINGERDirector BEDMINSTERALAN G  HARRISBEDMINSTERALAN G  HARRISSVP, Chief Medical Officer BEDMINSTERG THOMAS  HEATHVP, Sales and Marketing SALT LAKE CITYG THOMAS  HEATHVP, Marketing and Sales SALT LAKE CITYHUNTER  JACKSONPresident, CEO and Chairman SALT LAKE CITYHUNTER  JACKSONDirector SALT LAKE CITYJAMES U  JENSENJAMES U  JENSENVP, Corp Dev and Legal Affairs SALT LAKE CITYJOSEPH  KLEIN IIIDirector SALT LAKE CITYJOSEPH  KLEIN IIIDirector SALT LAKE CITYDONALD E  KUHLADirector SALT LAKE CITYDONALD E  KUHLADirector SALT LAKE CITYDONALD E  KUHLADirector BEDMINSTERJuergen  LasowskiSenior VP Business Development SALT LAKE CITYPierre  LegaultDirector BERKELEY HEIGHTSPierre  LegaultDirector BEDMINSTERTHOMAS B  MARRIOTT IIIVP, Development Research SALT LAKE CITYTHOMAS B  MARRIOTT IIIVP, Development Research SALT LAKE CITYMichael E  McDonnellVP, Human Resources SALT LAKE CITYGlenn R  MelroseVP, Human Resources SALT LAKE CITYGlenn R  MelroseSVP, Human Resources BEDMINSTERGERARD J  MICHELCFO & VP, Corp. Development SALT LAKE CITYGERARD J  MICHELCFO & VP, Corp. Development SALT LAKE CITYGERARD J  MICHELCFO & VP, Corp. Development BEDMINSTERALAN L  MUELLERVP, Discovery Research SALT LAKE CITYALAN L  MUELLERVP, Drug Discovery SALT LAKE CITYFrancois  NaderPresident, CEO and Director SALT LAKE CITYFrancois  NaderPresident, CEO and Director BEDMINSTEREDWARD F  NEMETHVP & Chief Scientific Officer SALT LAKE CITYEDWARD F  NEMETHVP & Chief Scientific Officer SALT LAKE CITYBRIAN  O'CALLAGHANBEDMINSTERBRIAN  O'CALLAGHANSVP & CCO BEDMINSTERTHOMAS N  PARKSDirector SALT LAKE CITYTHOMAS N  PARKSDirector SALT LAKE CITYSTEPHEN R  PARRISHVP, Manufacturing SALT LAKE CITYSTEPHEN R  PARRISHVP, Manufacturing SALT LAKE CITYEric  PauwelsPresident, NPS Pharma Int'l CAMBRIDGEEric  PauwelsPresident, NPS Pharma Int'l BEDMINSTERAndrew D  RackearSVP, General Coun. & Sec. BEDMINSTERAndrew D.  RackearSVP, General Counsel & Sec. BEDMINSTERALAN MARK  RAUCHVP, Chief Medical Officer SALT LAKE CITYALAN MARK  RAUCHVP, Chief Medical Officer SALT LAKE CITYJoseph J  RogusSVP, GTO & Supply Chain Mngmt GERMANTOWNJoseph J  RogusSVP, GTO & Supply Chain Mngmt BEDMINSTERCOTTRELL  SANDRAVP, Reg. Affairs & Drug Safety BEDMINSTERRachel R  SeliskerDirector SALT LAKE CITYRachel R  SeliskerDirector BEDMINSTERCALVIN  STILLERDirector SALT LAKE CITYCALVIN  STILLERDirector SALT LAKE CITYCALVIN  STILLERDirector BEDMINSTERED  STRATEMEIERSVP & General Counsel BEDMINSTERPETER G  TOMBROSDirector EAST RUTHERFORDPETER G  TOMBROSDirector BEDMINSTERPETER G  TOMBROSDirector SALT LAKE CITYPETER G  TOMBROSDirector SALT LAKE CITYGregory M  TorreSenior VP, Regulatory Affairs SALT LAKE CITYPersons related to Colin MD  Broom - VIROPHARMA INCNamePositionCity14159 Capital (GP, LLC10% Owner NEW YORK14159 capital (GP), LLC10% Owner NEW YORK14159 Capital (GP, LLC10% Owner NEW YORK14159 capital (GP), LLC10% Owner NEW YORK14159 capital (GP), LLC10% Owner NEW YORKAVENITS HOLDINGS INCGREENVILLEAVENTIS HOLDINGS INCGREENVILLEAVENTIS INCBRIDGEWATERAVENTIS INCAVENTIS INCBRIDGEWATERAVENTIS PHARMACEUTICALS INC10% Owner BRIDGEWATERBaker Biotech Capital (GP), LLC10% Owner NEW YORKBAKER BIOTECH CAPITAL GP LLC10% Owner NEW YORKBAKER BIOTECH CAPITAL GP LLC10% Owner NEW YORKBaker Biotech Capital (GP), LLC10% Owner NEW YORKBaker Biotech Capital (GP), LLC10% Owner NEW YORKBaker Biotech Capital (GP), LLC10% Owner NEW YORKBAKER BIOTECH CAPITAL II GP LLC10% Owner NEW YORKBaker Biotech Capital II (GP), LLC10% Owner NEW YORKBaker Biotech Capital II (GP), LLC10% Owner NEW YORKBaker Biotech Capital II (Z) (GP), LLC10% Owner NEW YORKBaker Biotech Capital III (GP), LLC10% Owner NEW YORKBaker Biotech Capital III (Z) (GP), LLC10% Owner NEW YORKBaker Biotech Capital III (Z) (GP), LLC10% Owner NEW YORKBAKER BROS CAPITAL GP LLC10% Owner NEW YORKBaker Bros. Capital (GP), LLC10% Owner NEW YORKBaker Bros. Capital (GP), LLC10% Owner NEW YORKBaker Bros. Capital (GP), LLC10% Owner NEW YORKBaker Brothers Life Sciences Capital (GP), LLC10% Owner NEW YORKBaker Brothers Life Sciences Capital (GP), LLC10% Owner NEW YORKFELIX  BAKERNEW YORKFELIX  BAKERNEW YORKFELIX  BAKERNEW YORKJULIAN  BAKERNEW YORKJULIAN  BAKERNEW YORKJULIAN  BAKERNEW YORKBAKER TISCH CAPITAL GP LLC10% Owner NEW YORKBAKER TISCH CAPITAL GP LLC10% Owner NEW YORKBaker / Tisch Capital (GP), LLC10% Owner NEW YORKBaker / Tisch Capital (GP), LLC10% Owner NEW YORKBaker / Tisch Capital (GP), LLC10% Owner NEW YORKFRANK  BALDINO JRDirector EXTONFRANK  BALDINO JRDirector EXTONPAUL A  BROOKEDirector EXTONColin MD  BroomVP & Chief Scientific Officer EXTONColin MD  BroomVP & Chief Scientific Officer EXTONColin MD  BroomVP & Chief Scientific Officer EXTONWILLIAM D MD  CLAYPOOLDirector EXTONWILLIAM D MD  CLAYPOOLDirector EXTONMARC  COLLETTROSEN MICHEL  DEROSEN MICHEL  DEChief Executive Officer EXTONROSEN MICHEL  DEDirector EXTONROSEN MICHEL  DEDirector EXTONMICHAEL R  DOUGHERTYDirector EXTONMICHAEL R  DOUGHERTYDirector EXTONTHOMAS F  DOYLETHOMAS F  DOYLEVP Strategic Initiatives EXTONTHOMAS F  DOYLEVP Strategic Initiatives EXTONRICHARD  FARLEYRICHARD  FARLEYVP, Human Resources EXTONRobert C.  FletcherV.P., Business Development EXTONROBERT  GLASERDirector EXTONROBERT  GLASERDirector EXTONROBERT  GLASERDirector EXTONJohn J.  KirbyV.P., Chief Accounting Officer EXTONJohn R  LeoneDirector EXTONJohn R  LeoneDirector EXTONJulie  McHughDirector EXTONMARK  MCKINLAYMARK  MCKINLAYVP Research & Development EXTONVINCENT  MILANOVINCENT  MILANOPresident, CEO & CFO EXTONVINCENT  MILANOPresident and CEO EXTONRichard Steven  MorrisChief Accounting Officer EXTONRichard Steven  MorrisChief Accounting Officer EXTONHOWARD H  PIENDirector EXTONHOWARD H  PIENDirector EXTONRobert  PietruskoVP, Regulatory & Quality EXTONRobert  PietruskoVP, Regulatory & Quality EXTONCharles A  Rowland JrChief Financial Officer EXTONCharles A  Rowland JrVP, Chief Financial Officer EXTONDANIEL B  SOLANDVP, Chief Operating Officer EXTONDANIEL B  SOLANDVP, Chief Operating Officer EXTONJoshua M  TarnoffVP, Commercial EXTONJoshua M  TarnoffVP, Chief Commerical Officer EXTONJohn Peter  Wolf IIIVP, General Counsel EXTONJohn Peter  Wolf IIIVP, General Counsel EXTONPersons related to Colin MD  Broom - Nabriva Therapeutics plcNamePositionCityAxel  BolteSOUTH PLAINFIELDColin MD  BroomChief Executive Officer EXTONDANIEL D  BURGESSSAN DIEGOMARK  CORRIGANMARLBOROUGHRobert  CrottySEATTLESteven P.  GeloneChief Development Officer KING OF PRUSSIAHBM BIOVENTURES CAYMAN LTD10% Owner GRAND CAYMANSAMUEL D  ISALYChau Quang  KhuongSAN DIEGOORBIMED ADVISORS LLCOrbiMed Capital GP V LLCNEW YORKCharles A  Rowland JrCHADDS FORDElyse G.  SeltzerChief Medical Officer KING OF PRUSSIAGary  SenderChief Financial Officer NEW YORKGeorge Harrison  TalbotDirector MORRISTOWNVivo Capital VIII, LLCPALO ALTOStephen W  WebsterEXTONJohn Peter  Wolf IIIEXTONPersons related to Colin MD  Broom - Nabriva Therapeutics Legacy plcNamePositionCityCarrie L.  BourdowKING OF PRUSSIAColin MD  BroomChief Executive Officer EXTONDANIEL D  BURGESSDirector SAN DIEGOMARK  CORRIGANDirector MARLBOROUGHRobert  CrottyGeneral Counsel & Corp Secreta SEATTLESteven P.  GeloneChief Development Officer KING OF PRUSSIAHBM BIOVENTURES CAYMAN LTD10% Owner GRAND CAYMANChau Quang  KhuongDirector SAN DIEGOFrancesco Maria  LavinoKING OF PRUSSIACharles A  Rowland JrDirector CHADDS FORDElyse G.  SeltzerChief Medical Officer KING OF PRUSSIAGary  SenderChief Financial Officer NEW YORKGeorge Harrison  TalbotDirector MORRISTOWNStephen W  WebsterDirector EXTON












 









Insider Trading - Broom Colin Md - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Broom Colin Md





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2015-02-21Equity Swap
2015-02-249:16 pm
N/AN/A
Nps Pharmaceuticals Inc
NPSP
Broom Colin MdDirector
24,313
$46
0(Direct)
View


2015-02-21Disposition
2015-02-249:16 pm
N/A2019-07-09
Nps Pharmaceuticals Inc
NPSP
Broom Colin MdDirector
36,000
$4.95
0(Direct)
View


2015-02-21Disposition
2015-02-249:16 pm
N/AN/A
Nps Pharmaceuticals Inc
NPSP
Broom Colin MdDirector
3,816
$0
0(Direct)
View


2015-02-21Disposition
2015-02-249:16 pm
N/AN/A
Nps Pharmaceuticals Inc
NPSP
Broom Colin MdDirector
29,759
$0
0(Direct)
View


2015-02-12Option Award
2015-02-204:48 pm
N/AN/A
Nps Pharmaceuticals Inc
NPSP
Broom Colin MdDirector
3,816
$0
3,816(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Sat, 22 Jul 2017 18:02:29 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  











Broom Colin MD Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      Broom Colin MD
                    

•   WEST CHESTER, PA
                      
How do I update this listing?




                                             Broom Colin MD is based out of West Chester.    WhaleWisdom has at least 19 insider transactions (Form 3,4,5) in our database for Broom Colin MD. 
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from Broom Colin MD, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




broom colin md


119 FRINGETREE DRIVE

WEST CHESTER
PA
                                                        
                                                    19380


                                                      Business Phone:
                                                      (908) 450-5300
SEC SIC CODE:2834-PHARMACEUTICAL PREPARATIONS







Recent SEC Filings




4 filed on 06/27/2017
4 filed on 02/09/2017
3 filed on 12/30/2016
4 filed on 02/24/2015
4 filed on 02/20/2015
4 filed on 02/14/2014
4 filed on 01/28/2014
4 filed on 01/10/2014
4 filed on 06/12/2013
4 filed on 02/15/2013
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free


































Nabriva - Management





Menu












Management



Colin BroomChief Executive Officer Colin Broom joined Nabriva Therapeutics in August 2014. He has a bachelor of science degree in pharmacology from University College, London and a bachelor of medicine and surgery degree from St. George’s Hospital Medical School, London. He is a Member of the UK Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine. Over the past 30 years Colin has been involved in all stages of drug development and commercialization. Most recently, he served as Chief Scientific Officer at ViroPharma, Inc., (now Shire). Previous positions have included a range of leadership positions with Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham and Glaxo (now GlaxoSmithKline).Robert CrottyGeneral CounselRobert Crotty joined Nabriva in June 2017. Mr. Crotty joins Nabriva with over a decade of experience in the pharmaceutical and biopharmaceutical industries, most recently as VP, General Counsel, Chief Compliance Officer and Secretary at Vernalis Therapeutics, Inc.  Mr. Crotty has a broad legal skill set with experience in corporate governance, securities filings, financing, business development, corporate law and commercial compliance.  Previously, Mr. Crotty worked in the life sciences industry with positions at Dendreon Corporation, NPS Pharmaceuticals and ImClone Systems Incorporated.  After law school, he worked at two law firms, Morgan, Lewis & Bockius and Norton Rose Fulbright.  Mr. Crotty obtained his law degree from the University of Pennsylvania and his undergraduate degree from Princeton University.Steven GeloneChief Scientific Officer and Head of Business DevelopmentSteven Gelone joined Nabriva Therapeutics in December 2014. He has a bachelor of sciences and doctorate in pharmacy degree from Temple University in Philadelphia. Over the past 20 years Steve has been involved in all stages of drug development and commercialization. He has served as Head of Clinical Research and Development at Spark Therapeutics, as well as Vice President of Development at ViroPharma Incorporated (now Shire). Previous roles include a leadership positions with GSK, Vicuron Pharmaceuticals and Temple University Schools of Pharmacy and Medicine. Francesco Maria LavinoChief Commercial OfficerFrancesco Maria Lavino joined Nabriva Therapeutics in July 2017 bringing nearly two decades of pharmaceutical sales and marketing experience. The last half of his career has been focused on anti-infective medications administered primarily in the hospital setting. He most recently served as AVP, Global Brand Leader Anti-Infective Portfolio at Merck & Co. Inc. (known as MSD outside the United States), where he was responsible for the development and implementation of the global marketing strategy for the whole Merck anti-bacterial portfolio. Prior to this role, Francesco was VP International Marketing for the Anti-Infectives Portfolio at Cubist Pharmaceuticals and previous roles at Merck included global brand leadership for the company’s antifungal portfolio and, before, he held positions in marketing and sales both at regional and country level. Francesco began his career in pharmaceutical sales at UCB Pharma and 3M in Italy. He has a Bachelor of Arts in Pharmacy from the Federico II University of Napoli, Italy and an MBA from SDA Bocconi School of Management in Milan, Italy Elyse SeltzerChief Medical OfficerElyse Seltzer joined Nabriva Therapeutics in May 2015. She has a bachelor of arts from the University of Pennsylvania and a medical degree from New York University School of Medicine. She completed her Internal Medicine training at the University of Pennsylvania Medical Center, and her Infectious Diseases training at Yale New Haven Hospital. Since 1999, Elyse has been involved in all stages of drug development and commercialization. Most recently she served as Vice President, Global Clinical Sciences and Operations at GlaxoSmithKline. Previously she was Chief Medical Officer at Tengion, and has held leadership positons at Centocor, Vicuron, where she led the development of dalbavancin and at SmithKline Beecham.Gary SenderChief Financial Officer Gary Sender has over 25 years of financial leadership experience in the pharmaceutical and biopharmaceutical industries, most recently as Chief Financial Officer and EVP at Synergy Pharmaceuticals. From 2009-2015, Mr. Sender served as Senior Vice President, Finance at Shire plc. supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. He was responsible for financial management and support of all commercial areas of Shire’s $6 billion Specialty Pharmaceutical and Rare Disease businesses, with an emphasis on resource allocation, financial forecasting, business cases and M&A. Prior to joining Shire, he was the founding CFO of Tengion – a biotechnology company in the field of Regenerative Medicine. Mr. Sender spent 15 years in a number of leadership roles within Merck, including Investor Relations, M&A Finance, Treasury and Divisional Financial Management. Mr. Sender holds a bachelor’s degree in Finance and Information Systems from Boston University and a master’s degree in Industrial Administration (MBA) with a concentration in Finance from Carnegie-Mellon University.David GarrettVice President, Corporate Controller and Head of Investor RelationsDave joined Nabriva in November 2015. He held previous finance roles with Covis Pharma, Auxilium, Shire and ViroPharma. Dave started his career in public accounting with KPMG and is a Certified Public Accountant. Dave received his Bachelor of Science and Master of Business Administration degrees from Villanova University. He is a member of the FEI, AICPA and PICPA.Werner HeilmayerVice President Research, CMC & IPWerner Heilmayer joined Nabriva Therapeutics in February 2006. He holds a PhD in organic chemistry. Having worked for almost 20 years in the pharmaceutical and biotech industry, Werner has gained significant experience in drug development and intellectual property. He has a strong track record in patent filing and is co-inventor of more than 10 international filed patent applications. Before joining Nabriva Werner held the position of Head of Chemistry of Sandoz's discovery unit. Werner played a major role in the Nabriva spin-off from Sandoz and served Nabriva as Head CMC and IP before he was appointed VP CMC & IP in June 2012.Ernie KellyVice President QualityErnest Kelly joined Nabriva Therapeutics full time in June 2016. He has a bachelor of arts degree in Chemistry from Millersville University and a Ph.D. in Physical Chemistry from Villanova University. Over the past 44 years Ernie has been involved in all stages of pharmaceutical development and commercialization, most recently as Vice President, Quality at Shire plc. Previous roles include leadership and technical positions in Quality and Compliance with ViroPharma (now Shire), Cephalon, Bio-Technology General Corp, Rhone Poulenc Rorer (now Sanofi), Merck and McNeil pharmaceutical companies. Ernie has been active in pharmaceutical trade associations and is a past chair of several PhRMA Technical Committees, past industry representative on USP Aerosol Advisory Panels and a past Adjunct Professor of Pharmaceuticals, Temple University, School of Pharmacy.Thomas LembckChief Information OfficerThomas Lembck joined Nabriva Therapeutics full time in July 2015.  For 13 years, he led the IT and Facility teams at ViroPharma Incorporated building a global organization to support the rapid growth of the organization and supported the company’s acquisition transition into Shire plc.   Prior to Viropharma, he worked with VisAlign, where he led various teams and projects focused on information systems and strategic planning for pharmaceutical companies including Schering-Plough, Pfizer, and Merck.  Thomas also has held multiple roles of escalating responsibility at Comptek Research, Raytheon, and ABB in Zurich, Switzerland.  At Nabriva, he has demonstrated technology leadership by crafting the requisite strategic vision to achieve business goals by offering a unique blend of executive acumen, global team-building and IT solutions development with strong ROI and operational effectiveness.  Thomas holds a master of business administration degree from Temple University, a bachelor of science degree from Rensselaer Polytechnic Institute in Electrical Engineering, and several executive training certificates from both the Bell Leadership program at University of North Carolina and Dartmouth’s Tuck Business School. William SargentVice President Commercial StrategyWill Sargent joined Nabriva September 2015. Mr. Sargent joins Nabriva with over two decades of experience in the biopharmaceutical industry, including leadership roles for multiple product and line extension launches and as a sell-side analyst on Wall Street. Most recently, he served as Vice President, Orthopedic Business Unit at Auxilium Pharmaceuticals (now ENDO International) where he led the company's marketing and sales team advancing XIAFLEX® for the treatment of Dupuytren's contracture and development of additional pipeline indications. Mr. Sargent received his Bachelor of Arts in Biology from Johns Hopkins University and an MBA from the University of Washington

 






 SECGems: Broom Colin MD 







































  







			Data feeds now available
			Excel / CSV / Java / Python /etc 
Database
Learn more









  




  


  






























 Broom Colin MD 
		     










 Info




 Ownership




 Filings
58















←


 1 


 2 


 3 


→



 Filings:    (1 of 20 - Total: 58)









		
			June 27, 2017 .
		
	


				Issuer
			

 
					Nabriva Therapeutics Plc 
					

 
					NBRV
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					        Director,               
					    Officer,                
					 Chief Executive Officer, 
					
					
					]
				

Signed By

 Gary L Sender by power of attorney






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001104659-17-041898.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				June 23, 2017 
			







Ordinary Shares 


 
 	[J : Other acqui. or dispo.] 
 	 1,595 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
1,595


Ordinary Shares 


 
 	[J : Other acqui. or dispo.] 
 	 155,817 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
155,817 
 
 
  
 	[ By grantor retained annuity trust ] 
 
 
 
 
 

 



Stock Option 


 
 	[J : Other acqui. or dispo.] 
 	 158,270 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
158,270 
 
 
 
 
 
 	[ Underlying Securities: Ordinary Shares ]
 
 
 
 	158,270 shares


Stock Option 


 
 	[J : Other acqui. or dispo.] 
 	 196,900 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
196,900 
 
 
 
 
 
 	[ Underlying Securities: Ordinary Shares ]
 
 
 
 	196,900 shares


Stock Option 


 
 	[J : Other acqui. or dispo.] 
 	 151,000 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
151,000 
 
 
 
 
 
 	[ Underlying Securities: Ordinary Shares ]
 
 
 
 	151,000 shares


Stock Option 


 
 	[J : Other acqui. or dispo.] 
 	 261,000 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
261,000 
 
 
 
 
 
 	[ Underlying Securities: Ordinary Shares ]
 
 
 
 	261,000 shares













		
			Feb. 9, 2017 .
		
	


				Issuer
			

 
					Nabriva Therapeutics AG 
					

 
					NBRV
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 Chief Executive Officer, 
					
					
					]
				

Signed By

 Gary L Sender by power of attorney






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001104659-17-007828.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Feb. 7, 2017 
			







Stock Option 


 
 	[A : Grant / award] 
 	 26,100 
shares 
  
 
 
 	x 
 	$0.00/sh
Total owned:
26,100 
 
 
 
 
 
 	[ Underlying Securities: Common Shares ]
 
 
 
 	26,100 shares













		
			Dec. 30, 2016 .
		
	


				Issuer
			

 
					Nabriva Therapeutics AG 
					

 
					NBRV
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 Chief Executive Officer, 
					
					
					]
				

Signed By

 Gary L Sender by power of attorney






		Preview. 
	

 
			View filing ...
		






				3
			




 
					0001104659-16-164570.nc
				

 
					XML (1) 
				





					Ownership: Initial statement of beneficial ownership of securities. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Dec. 30, 2016 
			







Common Shares 


Total owned:
159


Common Shares 


Total owned:
15,582 
 
 
  
 	[ By grantor retained annuity trust ] 
 
 
 
 
 

 



Stock Option 


  
 
 
 
 
 
 
 
 
 
 
 	[ Underlying Securities: Common Shares ]
 
 
 
 	15,827 shares


Stock Option 


  
 
 
 
 
 
 
 
 
 
 
 	[ Underlying Securities: Common Shares ]
 
 
 
 	19,690 shares


Stock Option 


  
 
 
 
 
 
 
 
 
 
 
 	[ Underlying Securities: Common Shares ]
 
 
 
 	15,100 shares













		
			Feb. 24, 2015 .
		
	


				Issuer
			

 
					NPS PHARMACEUTICALS INC 
					

 
					NPSP
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					        Director,               
					
					
					
					
					]
				

Signed By

 Colin Broom by Jill Thompson as attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001104659-15-013584.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Feb. 21, 2015 
			







Common Stock 


 
 	[U : Disp. in a change of control trans.] 
 	 24,313 
shares 
  
 
 
 	x 
 	$46.00/sh
Total owned:
0


Stock Options (right to buy) 


 
 	[D : Disp to issuer] 
 	 36,000 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	36,000 shares


Restricted Stock Units 


 
 	[D : Disp to issuer] 
 	 3,816 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	3,816 shares


Deferred Stock Units 


 
 	[D : Disp to issuer] 
 	 29,759 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	29,759 shares













		
			Feb. 20, 2015 .
		
	


				Issuer
			

 
					NPS PHARMACEUTICALS INC 
					

 
					NPSP
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					        Director,               
					
					
					
					
					]
				

Signed By

 Colin Broom by Jill Thompson as attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001104659-15-012653.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Feb. 12, 2015 
			







Restricted Stock Units 


 
 	[A : Grant / award] 
 	 3,816 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
3,816 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	3,816 shares













		
			Feb. 14, 2014 .
		
	


				Issuer
			

 
					NPS PHARMACEUTICALS INC 
					

 
					NPSP
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					        Director,               
					
					
					
					
					]
				

Signed By

 Colin Broom by Jill Thompson as attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0000890465-14-000026.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Feb. 12, 2014 
			







Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 15,188 
shares
Total owned:
24,313


Restricted Stock Units 


 
 	[A : Grant / award] 
 	 4,572 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
4,572 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	4,572 shares


Restricted Stock Units 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 15,188 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	15,188 shares













		
			Jan. 28, 2014 .
		
	


				Issuer
			

 
					VIROPHARMA INC 
					

 
					VPHM
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 VP & Chief Scientific Officer, 
					
					
					]
				

Signed By

 J Peter Wolf attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001127602-14-003233.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Jan. 24, 2014 
			







Common Stock 


 
 	[U : Disp. in a change of control trans.] 
 	 154,058 
shares 
  
 
 
 	x 
 	$50.00/sh
Total owned:
0


Common Stock 


 
 	[A : Grant / award] 
 	 48,878 
shares
Total owned:
48,878


Common Stock 


 
 	[D : Disp to issuer] 
 	 48,878 
shares
Total owned:
0


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 34,932 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	34,932 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 33,439 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	33,439 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 49,975 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	49,975 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 52,593 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	52,593 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 36,920 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	36,920 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 50,000 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	50,000 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 40,261 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	40,261 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 40,261 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	40,261 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 27,265 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	27,265 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 35,723 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	35,723 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 34,570 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	34,570 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 32,516 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	32,516 shares


Employee Stock Option (Right to Buy) 


 
 	[D : Disp to issuer] 
 	 40,000 
shares
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	40,000 shares













		
			Jan. 10, 2014 .
		
	


				Issuer
			

 
					VIROPHARMA INC 
					

 
					VPHM
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 VP & Chief Scientific Officer, 
					
					
					]
				

Signed By

 J Peter Wolf attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001127602-14-001716.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Jan. 8, 2014 
			







Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 90,000 
shares 
  
 
 
 	x 
 	$1.84/sh
Total owned:
122,056


Common Stock 


 
 	[F : Pmt of exercise price or tax liab] 
 	 6,914 
shares 
  
 
 
 	x 
 	$49.80/sh
Total owned:
115,142


Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 10,000 
shares 
  
 
 
 	x 
 	$5.91/sh
Total owned:
125,142


Common Stock 


 
 	[F : Pmt of exercise price or tax liab] 
 	 1,551 
shares 
  
 
 
 	x 
 	$49.80/sh
Total owned:
123,591


Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 13,080 
shares 
  
 
 
 	x 
 	$8.86/sh
Total owned:
136,671


Common Stock 


 
 	[F : Pmt of exercise price or tax liab] 
 	 2,773 
shares 
  
 
 
 	x 
 	$49.80/sh
Total owned:
133,898


Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 5,001 
shares 
  
 
 
 	x 
 	$9.96/sh
Total owned:
138,899


Common Stock 


 
 	[F : Pmt of exercise price or tax liab] 
 	 1,166 
shares 
  
 
 
 	x 
 	$49.80/sh
Total owned:
137,733


Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 5,025 
shares 
  
 
 
 	x 
 	$9.99/sh
Total owned:
142,758


Common Stock 


 
 	[F : Pmt of exercise price or tax liab] 
 	 1,175 
shares 
  
 
 
 	x 
 	$49.80/sh
Total owned:
141,583


Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 7,407 
shares 
  
 
 
 	x 
 	$13.50/sh
Total owned:
148,990


Common Stock 


 
 	[F : Pmt of exercise price or tax liab] 
 	 2,231 
shares 
  
 
 
 	x 
 	$49.80/sh
Total owned:
146,759


Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 6,561 
shares 
  
 
 
 	x 
 	$15.24/sh
Total owned:
153,320


Common Stock 


 
 	[F : Pmt of exercise price or tax liab] 
 	 2,196 
shares 
  
 
 
 	x 
 	$49.80/sh
Total owned:
151,124


Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 5,068 
shares 
  
 
 
 	x 
 	$19.73/sh
Total owned:
156,192


Common Stock 


 
 	[F : Pmt of exercise price or tax liab] 
 	 2,134 
shares 
  
 
 
 	x 
 	$49.80/sh
Total owned:
154,058


Incentive Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 90,000 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
30,000 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	90,000 shares


Employee Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 10,000 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	10,000 shares


Employee Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 13,080 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
36,920 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	13,080 shares


Employee Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 5,001 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
0 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	5,001 shares


Employee Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 5,025 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
49,975 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	5,025 shares


Employee Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 7,407 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
52,593 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	7,407 shares


Employee Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 6,561 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
33,439 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	6,561 shares


Employee Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 5,068 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
34,932 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	5,068 shares













		
			June 12, 2013 .
		
	


				Issuer
			

 
					VIROPHARMA INC 
					

 
					VPHM
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 VP & Chief Scientific Officer, 
					
					
					]
				

Signed By

 J Peter Wolf attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001127602-13-020167.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				June 10, 2013 
			







Employee Stock Option (Right to Buy) 


 
 	[A : Grant / award] 
 	 32,516 
shares
Total owned:
32,516 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	32,516 shares













		
			Feb. 15, 2013 .
		
	


				Issuer
			

 
					NPS PHARMACEUTICALS INC 
					

 
					NPSP
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					        Director,               
					
					
					
					
					]
				

Signed By

 Edward Stratemeier as Attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001474064-13-000037.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Feb. 13, 2012 
			







Restricted Stock Units 


 
 	[A : Grant / award] 
 	 15,188 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
15,188 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	15,188 shares













		
			Feb. 11, 2013 .
		
	


				Issuer
			

 
					NPS PHARMACEUTICALS INC 
					

 
					NPSP
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					        Director,               
					
					
					
					
					]
				

Signed By

 Edward Stratemeier as Attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001474064-13-000022.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Feb. 7, 2013 
			







Common stock 


 
 	[J : Other acqui. or dispo.] 
 	 15,225 
shares
Total owned:
15,225


Common stock 


 
 	[S : Open market or private sale] 
 	 6,100 
shares 
  
 
 
 	x 
 	$8.74/sh
Total owned:
9,125













		
			Jan. 7, 2013 .
		
	


				Issuer
			

 
					VIROPHARMA INC 
					

 
					VPHM
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 VP & Chief Scientific Officer, 
					
					
					]
				

Signed By

 J Peter Wolf attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001127602-13-001308.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Jan. 3, 2013 
			







Employee Stock Option (Right to Buy) 


 
 	[A : Grant / award] 
 	 34,570 
shares
Total owned:
34,570 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	34,570 shares













		
			Dec. 28, 2012 .
		
	


				Issuer
			

 
					VIROPHARMA INC 
					

 
					VPHM
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 VP & Chief Scientific Officer, 
					
					
					]
				

Signed By

 J Peter Wolf attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001127602-12-035159.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Dec. 27, 2012 
			







Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 10,000 
shares 
  
 
 
 	x 
 	$1.84/sh
Total owned:
30,167


Incentive Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 10,000 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
120,000 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	10,000 shares













		
			Dec. 28, 2012 .
		
	


				Issuer
			

 
					VIROPHARMA INC 
					

 
					VPHM
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 VP & Chief Scientific Officer, 
					
					
					]
				

Signed By

 J Peter Wolf attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4/A
			




 
					0001127602-12-035162.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Dec. 24, 2012 
			







Common Stock 


 
 	[S : Open market or private sale] 
 	 17,500 
shares 
  
 
 
 	x 
 	$22.5315/sh
Total owned:
20,167













		
			Dec. 27, 2012 .
		
	


				Issuer
			

 
					VIROPHARMA INC 
					

 
					VPHM
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 VP & Chief Scientific Officer, 
					
					
					]
				

Signed By

 J Peter Wolf attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001127602-12-035085.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Dec. 24, 2012 
			







Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 17,500 
shares 
  
 
 
 	x 
 	$1.84/sh
Total owned:
55,167


Common Stock 


 
 	[S : Open market or private sale] 
 	 17,500 
shares 
  
 
 
 	x 
 	$22.5315/sh
Total owned:
37,667


Incentive Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 17,500 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
112,500 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	17,500 shares













		
			Dec. 12, 2012 .
		
	


				Issuer
			

 
					VIROPHARMA INC 
					

 
					VPHM
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 VP & Chief Scientific Officer, 
					
					
					]
				

Signed By

 J Peter Wolf attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001127602-12-033702.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Dec. 10, 2012 
			







Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 10,000 
shares 
  
 
 
 	x 
 	$5.91/sh
Total owned:
47,667


Common Stock 


 
 	[S : Open market or private sale] 
 	 10,000 
shares 
  
 
 
 	x 
 	$24.0672/sh
Total owned:
37,667


Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 50,000 
shares 
  
 
 
 	x 
 	$8.86/sh
Total owned:
87,667


Common Stock 


 
 	[S : Open market or private sale] 
 	 50,000 
shares 
  
 
 
 	x 
 	$24.0672/sh
Total owned:
37,667


Common Stock 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 14,999 
shares 
  
 
 
 	x 
 	$9.96/sh
Total owned:
52,666


Common Stock 


 
 	[S : Open market or private sale] 
 	 14,999 
shares 
  
 
 
 	x 
 	$24.0672/sh
Total owned:
37,667


Employee Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 10,000 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
10,000 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	10,000 shares


Employee Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 50,000 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
50,000 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	50,000 shares


Employee Stock Option (Right to Buy) 


 
 	[M : Exer. or conv. of deriv. security exempted] 
 	 14,999 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
5,001 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	14,999 shares













		
			June 6, 2012 .
		
	


				Issuer
			

 
					VIROPHARMA INC 
					

 
					VPHM
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					
					    Officer,                
					 VP & Chief Scientific Officer, 
					
					
					]
				

Signed By

 J Peter Wolf attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001127602-12-019481.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				June 4, 2012 
			







Employee Stock Option (Right to Buy) 


 
 	[A : Grant / award] 
 	 35,723 
shares
Total owned:
35,723 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	35,723 shares













		
			May 23, 2012 .
		
	


				Issuer
			

 
					NPS PHARMACEUTICALS INC 
					

 
					NPSP
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					        Director,               
					
					
					
					
					]
				

Signed By

 Edward Stratemeier as Attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001474064-12-000043.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				May 16, 2012 
			







Deferred Stock Units 


 
 	[A : Grant / award] 
 	 403 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
29,759 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	403 shares













		
			Feb. 9, 2012 .
		
	


				Issuer
			

 
					NPS PHARMACEUTICALS INC 
					

 
					NPSP
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					        Director,               
					
					
					
					
					]
				

Signed By

 Edward Stratemeier as Attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001474064-12-000021.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Feb. 7, 2012 
			







Common Stock 


 
 	[A : Grant / award] 
 	 15,225 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
15,225













		
			Jan. 19, 2012 .
		
	


				Issuer
			

 
					NPS PHARMACEUTICALS INC 
					

 
					NPSP
				


				Reporting Owner
			

 
					Broom Colin MD 
					


					[
					
					        Director,               
					
					
					
					
					]
				

Signed By

 Edward Stratemeier as Attorney-in-fact






		Preview. 
	

 
			View filing ...
		






				4
			




 
					0001474064-12-000003.nc
				

 
					XML (1) 
				





					Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
				






				Period ending 
			

				Jan. 17, 2012 
			







Deferred Stock Units 


 
 	[A : Grant / award] 
 	 2,278 
shares 
  
 
 
 	x 
 	$0/sh
Total owned:
29,356 
 
 
 
 
 
 	[ Underlying Securities: Common Stock ]
 
 
 
 	2,278 shares










 





db
 
 










































Colin Broom, MD - Biography

















































































Log in






E-mail



Password







Remember




Forgot password ?









Become a member for free
Sign up





Sign up




New memberSign up for FREE


New customerDiscover our portfolios












 United States
 United Kingdom
 France
 Deutschland
 Schweiz (DE)
 Suisse (FR)










Settings

            Dynamic quotes 


OFFON

















Markets
Equities
North AmericaEuropeAsiaOceaniaMiddle East� More Equities

Indexes
DOW JONESS&P 500NASDAQ 100TSX COMPFTSE 100� More Indexes

Currency / Forex
EUR / USDGBP / USDUSD / JPYUSD / CADAUD / USD� More Currencies

Commodities
GOLDCrude Oil (WTI)Crude Oil (BRENT)SILVERPLATINUM� More Commodities


 News
Latest News
CompaniesMarketsEconomyCurrency / ForexCommoditiesInterest RatesBusiness LeadersFinancial calendarEconomic calendar

Listed company
Analyst reco.RumorsIPOsCapital Markets TransactionsNew ContractsProfits warningsAppointmentsPress ReleasesEventsCorporate actions

Sector News
EnergyBasic MaterialsIndustrialsConsumer CyclicalConsumer Non-CyclicalFinancialsHealthcareTechnologyTelecommunications ServicesUtilities


 Analysis
All AnalysisCommentariesIndex AnalysisStock Trading StrategiesCommodity AnalysisForex Analysis

 Stock Picks
All stock picks

 Portfolios
My Portfolio
Virtual portfolios
4-Traders Portfolios
European PortfolioUSA PortfolioAsian Portfolio


 Screeners
Market Screener HomeFundamental Analyse
Top Investor RatingTop Trading RatingTop ConsensusGrowth stocksYield stocksLow valuations

Technical Analysis
Oversold stocksOverbought stocksClose to resistancesClose to supportsAccumulation phaseMost volatile stocks


 Watchlists
My Watchlists
Watchlists
Top Lists
Yield stocksGrowth stocksUndervalued Stocks


 Top / Flop
Top News
Most Read NewsHot News

Top Fundamentals
Top CapitalizationTop YieldTop PERTop ConsensusTop Fundamentals

Top Technicals
Top RSIUnusual volumesTop GapsTop STIM

Top Movers
Top USATop CanadaTop U.K.Top GermanyTop EuropeTop Asia


 Tools
Market ScreenerDynamic chartFinancial calendarEconomic calendarSector researchCurrency converter

 Our Services
Premium AccessDiscover our Services

 



















 






4-Traders Homepage  >  News  >  Business Leaders  >  Business Leaders Biography


Business Leaders




Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors HomeAll newsMost read newsBusiness Leaders Biography


 
















Colin Broom, MD

Age : 61Public asset : 1,649,678 USDLinked companies :  Nabriva Therapeutics PLC - ADR -  NPS Pharmaceuticals, Inc. 





Summary 



Dr. Colin Broom, MD, is a Member at Royal College of Physicians.He  is on the Board of Directors at Nabriva Therapeutics AG, NPS Pharmaceuticals, Inc. and Nabriva Therapeutics Plc. Dr. Broom was previously employed as Chief Scientific Officer & Vice President by ViroPharma, Inc., VP-European Clinical Development & Medical Affairs by Amgen, Inc., Senior Vice President-Global Clinical Development by Hoechst Marion Roussel, Inc., and Vice President by The Gi Co., Inc.He received his undergraduate degree from the University College London and a doctorate degree from St. George's University of London.



Current positions of Colin Broom, MD 









 NameTitle
Since
 Nabriva Therapeutics PLC - ADR(Biotechnology & Medical Research)
Chief Executive Officer & Director
- NPS Pharmaceuticals, Inc.
Independent Director
2009Nabriva Therapeutics AG
Chief Executive Officer & Director
2014Royal College of Physicians
Member
-



Holdings of Colin Broom, MD 










 NameEquities%Valuation

Nabriva Therapeutics Plc157,4120.58%1,649,678 USD



Colin Broom, MD: Personal Network 







 NameLinked companies

Robert L. Crotty Nabriva Therapeutics PLC - ADRNabriva Therapeutics AGNPS Pharmaceuticals, Inc. 

Daniel D. Burgess Nabriva Therapeutics PLC - ADRNabriva Therapeutics AG 

Axel Bolte Nabriva Therapeutics PLC - ADRNabriva Therapeutics AG 

Mark H. N. Corrigan Nabriva Therapeutics PLC - ADRNabriva Therapeutics AG 

Chau Quang Khuong Nabriva Therapeutics PLC - ADRNabriva Therapeutics AG 

Gary L. Sender Nabriva Therapeutics PLC - ADRNabriva Therapeutics AG 

Stephen W. Webster Nabriva Therapeutics PLC - ADRNabriva Therapeutics AG 

Charles A. Rowland Nabriva Therapeutics PLC - ADRNabriva Therapeutics AG 

Elyse G. Seltzer Nabriva Therapeutics PLC - ADRNabriva Therapeutics AG 

George Harrison Talbot Nabriva Therapeutics PLC - ADRNabriva Therapeutics AG 




Most Read News 




07/17 CHARLES SCHWAB : Low-fee BlackRock funds reel in cash but earnings disappoint



07/17DJCHARLES SCHARF : Bank of New York Mellon Names Former Visa Executive Scharf CEO and Chairman



07/17 PHILIP GREEN : You're hired - UK 'Apprentice' star Brady to chair Philip Green's company



07/17DJRUPERT MURDOCH : Tesla Names James Murdoch and Linda Johnson Rice to Board -- Update



07/17DJJAMES MURDOCH : Tesla Names James Murdoch and Linda Johnson to Board of Directors



07/18DJMARK LIGHT : Top Company News of the Day



07/18DJNELSON PELTZ : Peltz Goes on Offense In Break From Form -- WSJ



07/17 DAVID HENRY : Didn't pay your Macy's bill? Expect a text from Citigroup



07/17DJMARK LIGHT : Top Company News of the Day



07/17DJNELSON PELTZ : Peltz Seeks P&G Board Seat -- WSJ



More news

 


            © 2017 People and Ownership :    









Advertisement








Colin Broom, MD : Connections 



 Blueprint Medicines Corp









Charles A. Rowland




 Nabriva Therapeutics PLC - ADR









Robert L. CrottyDaniel D. BurgessAxel BolteMark H. N. CorriganChau Quang KhuongGary L. SenderStephen W. WebsterCharles A. RowlandElyse G. SeltzerGeorge Harrison Talbot




 Viking Therapeutics Inc









Stephen W. WebsterCharles A. Rowland




 Ophthotech Corp









Axel Bolte




 Spark Therapeutics Inc









Stephen W. Webster




 Cidara Therapeutics Inc









Daniel D. Burgess




 Pieris Pharmaceuticals Inc









Chau Quang Khuong




 Novelion Therapeutics Inc (USA)









Mark H. N. Corrigan




 Cardiome Pharma Corp









Mark H. N. Corrigan




AtoxBio, Inc.
                                            








Daniel D. Burgess





Synlogic, Inc.
                                            








Chau Quang Khuong





Allena Pharmaceuticals, Inc.
                                            








Axel Bolte





Inspire Medical Systems, Inc.
                                            








Chau Quang Khuong





Kolltan Pharmaceuticals, Inc.
                                            








Axel Bolte





Nabriva Therapeutics AG
                                            








Robert L. CrottyDaniel D. BurgessAxel BolteMark H. N. CorriganChau Quang KhuongGary L. SenderStephen W. WebsterCharles A. RowlandElyse G. SeltzerGeorge Harrison Talbot





SV Life Sciences Advisers LLP
                                            








Daniel D. Burgess





Cerapedics, Inc.
                                            








Chau Quang Khuong





Lux Biosciences, Inc.
                                            








Axel Bolte





Nextcure, Inc.
                                            








Chau Quang Khuong





HBM Partners AG (Investment Management)
                                            








Axel Bolte





 







Popular Business Leaders 


 

Bernard Arnault
Mary Barra
Lloyd Blankfein
Michael Bloomberg
Yannick Bollor�
Warren Buffett
Antony Burgmans
Jean-paul Clozel
Gary Cohn
Jamie Dimon
Ralph Dommermuth
Sebastian Ebel
John Edwards
David Einhorn
Jeff Fettig
Mark Fields
Carlos Ghosn
Terry Gou
David Henry
Carl Icahn
Michel Landel
Daniel Loeb
Jack Ma
John Mackey
Marissa Mayer
Lakshmi Mittal
Oscar Munoz
Rupert Murdoch
Elon Musk
Peter Nicholas
John Paulson
Nelson Peltz
Georges Plassat
Hasso Plattner
Thomas Rabe
Giuseppe Recchi
Wolfgang Reitzle
Urs Rohner
Wilbur Ross
Charles Schwab
Igor Sechin
Pascal Soriot
George Soros
Rupert Stadler
Bernard Tapie
John Williamson
Thomas Wilson
Dieter Zetsche
Mark Zuckerberg



A-Z Business Leaders




 



























4-traders.com :MarketsNewsAnalysisStock PicksPortfoliosScreenersWatchlistsTop / FlopToolsOur ServicesAbout :Surperformance SASContact usAdvertiseLegal informationsAbout usStay Connected :FacebookTwitterPartners :B�rse: Aktien, Kurse und NachrichtenBest tweets 




   Copyright � 2017 Surperformance. All rights reserved.  












 














Slave








Broom by Philippe Starck


















































































Broom by StarckBroom is reclaimed, recyclable – and designed to last. Made in America from 75% waste polypropylene and 15% reclaimed wood fiber that would normally be swept into the trash. That’s why we call it Broom.




new_arrivalBROOM STACKING CHAIR
				$ 225			6 colorsnew_arrivalBROOM 24 COUNTER STOOL
				$ 400			6 colorsnew_arrivalBROOM 30 BARSTOOL
				$ 400			6 colors 












Film






Broom.
A short film. 

 



















BROOM STACKING CHAIR 

Biomuseo, Panama. By: Frank Gehry. Photo: Geteca. Download here


 



BROOM STACKING CHAIR 

Carben Restaurant, Ottawa, Canada. By: One80 Design. Download here


 



BROOM 24 COUNTER STOOL 

Courtepaille, Olivet, France. By: Philippe Avanzi. Download here


 



BROOM STACKING CHAIR 

New Baltimore Design School, Baltimore, MD. By: Ziger Snead. Download here


 



BROOM 30 BARSTOOL 

The Armory Show Champagne Lounge, NYC. By: Bade Stageberg Cox. Download here


 



BROOM STACKING CHAIR 

Private Residence, Atlanta, GA. Photo: Andrew Thomas Lee. Download here


 










 

Story
Emeco + Philippe StarckThe Story


Materials






Bits and piecesRead more about reclaimed wood polypropylene 

 










 


1 Inch by Jasper Morrison7 Product Variations, Various Finishes1006 Navy Collection6 Product Variations, 2 Finishes1104 Navy Collection with Wood Seat6 Product Variations, 3 Wood Options111 Navy Chair with Coca-Cola6 Color VariationsNavy Upholstered Collection8 Product Variations, 2 Finishes1951 by BMW3 Product Variations, 10 Color Options20-06 by Norman Foster8 Product VariationsAlfi by Jasper Morrison9 Product Variations, 5 Color OptionsBroom by Philippe Starck3 Product Variations, 6 Color OptionsEmeco Stool by Philippe Starck3 Product Variations, 2 FinishesOccasional Table by Philippe Starck3 Product VariationsHeritage by Philippe Starck6 Product Variations, 2 FinishesHudson by Philippe Starck10 Product Variations, 2 FinishesIcon by Philippe Starck3 Product Variations, 2 FinishesKong by Philippe Starck6 Product Variations, 2 FinishesLancaster by Michael Young6 Product Variations, 5 Color OptionsNine-0 by Ettore Sottsass12 Product Variations, 5 Color OptionsParrish by Konstantin Grcic10 Product Variations, 11 Seat OptionsRun by Sam Hecht and Kim Colin13 Product variations, 4 finishesSezz by Christophe Pillet6 Product VariationsSoSo by Jean Nouvel3 Product VariationsSu by Nendo6 Product Variations, 15 Color OptionsSuperlight by Frank Gehry1 Product variationCafé Table by Starck 


















Stock Screener - Yahoo FinanceHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreYahooSearchSearch0U.S. Markets closedS&P 5002,472.54-0.91 (-0.04%)Dow 3021,580.07-31.71 (-0.15%)LISTENAetna's CEO Mark Bertolini on the future of the health care systemBertolini shares how a life-threatening injury shaped his views on health care.Insider TransactionsDefault CriteriaInsider & Restricted Shareholder Transactions1-4 of 4 resultsResults were generated a few mins ago. Pricing data is updated frequently. Currency in USDSymbolDateSharesProceedsTransaction DetailsNBRV2017-06-22155,817N/AAcquisition (Non Open Market) at $0.00 per share.NBRV2017-06-221,595N/AAcquisition (Non Open Market) at $0.00 per share.NBRV2016-12-29N/AN/AStatement of OwnershipNBRV2016-12-29N/AN/AStatement of OwnershipA former biotech executive who's living with terminal cancer wants to reset expectations about new cancer treatmentsBusiness Insider2 Dudes in a Car: Blissing out in the Lincoln ContinentalYahoo FinanceWhy it might be ‘dangerous’ for IBM to turn itself around: professorYahoo FinanceYahoo Small BusinessData DisclaimerHelpSuggestionsPrivacyAbout Our AdsTerms (Updated)





